- Home
- AARD
as 05-13-2025 4:00pm EST
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 154.9M | IPO Year: | 2025 |
| Target Price: | $31.50 | AVG Volume (30 days): | 69.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.88 - $19.58 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Aardvark Therapeutics Inc. Common Stock News
AARD Breaking Stock News: Dive into AARD Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Aardvark Therapeutics to Present at Upcoming Investor Conferences in May
MT Newswires
15 days ago
Top Premarket Gainers
GlobeNewswire
a month ago
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights
Investor's Business Daily
2 months ago
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower
Insider Monkey
2 months ago
Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month
Insider Monkey
2 months ago
Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently
Compare AARD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AARD Aardvark Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.